EDIT vs TFC · rev $32.3M vs rev $24.54B
Editas Medicine Inc (EDIT) versus TFC (TFC) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
TFC (TFC) common stock.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported TFC revenue for 2025-12-31 was $24.54B. Net income was $5.31B. Revenue was down 2.1% from 2024-12-31 to 2025-12-31. TFC currently screens at market cap $0.
EDIT currently screens at market cap $375.2M. TFC currently screens at market cap $0.
Not investment advice. Open the EDIT and TFC stock pages for the full models.
Not investment advice.